文献速递传染病防控与疫情报告免疫规划

加拿大不列颠哥伦比亚省温哥华都会区2021-2023年放松COVID-19非药物干预后百日咳鲍特菌感染情况

Bordetella pertussis infection following relaxation of COVID-19 non-pharmaceutical interventions in 2021-2023 in Vancouver metropolitan area, British Columbia, Canada.
PubMed 文献 · Vaccine · 2024-05-25

研究对温哥华都会区25-51岁学校教职工每年采集血样(n=65),检测抗百日咳毒素IgG。2021-2022年血清转化率为4.6/100人年,2022-2023年为14.9/100人年(P=0.127)。抗PT IgG几何平均浓度2022年较2021年显著下降,2023年较2022年显著上升。尽管报告病例少,血清学证据提示放松NPI后百日咳鲍特菌循环恢复。

要点

  • 2021-2022年血清转化率4.6/100人年,2022-2023年14.9/100人年,P=0.127
  • 抗PT IgG几何平均浓度2022年较2021年显著下降(p=0.001),2023年较2022年显著上升(p=0.0006)
  • 尽管报告病例少,血清学证据提示放松COVID-19 NPI后百日咳鲍特菌循环恢复

核心结论

  • 2022至2023年间百日咳鲍特菌血清学证据增加,尽管报告病例少,提示放松COVID-19非药物干预后百日咳鲍特菌循环恢复。

研究设计与样本

  • 在加拿大不列颠哥伦比亚省温哥华都会区每年随机选取25-51岁学校教职工(n=65)采集血样,2021-2023年每年检测抗百日咳毒素IgG。
  • 血清转化定义为:前一年抗PT IgG低于定量下限而当年可定量,或两年间抗PT IgG升高>4倍。
  • 同时检测抗白喉类毒素IgG并应用类似血清转化标准,以排除因接种破伤风-白喉-无细胞百日咳(Tdap)疫苗导致的血清转化。

主要发现

  • 2021至2022年有3名受试者符合抗PT IgG血清转化标准,2022至2023年有9名,血清转化率分别为4.6/100人年和14.9/100人年,P=0.127。
  • 无受试者符合Tdap疫苗接种标准。
  • 抗PT IgG几何平均浓度2022年较2021年显著下降:4.8 IU/ml(95%CI 3.8-5.9) vs 6.4 IU/ml(95%CI 4.9-8.2),p=0.001。
  • 抗PT IgG几何平均浓度2023年较2022年显著上升:6.5 IU/ml(95%CI 4.9-8.5) vs 4.8 IU/ml(95%CI 3.8-5.9),p=0.0006。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021-2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021-2023. METHODS: Randomly selected blood samples from school staff 25-51 years old (n = 65) were collected yearly between 2021-2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter "seroconversion") was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap). RESULTS: Three subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8-5.9) vs. 6.4 IU/ml (95 % CI, 4.9-8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9-8.5) vs. 4.8 IU/ml (95 % CI, 3.8-5.9; p = 0.0006), respectively. DISCUSSION: Serological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Reicherz F, Li S, Watts AA, et al. Bordetella pertussis infection following relaxation of COVID-19 non-pharmaceutical interventions in 2021-2023 in Vancouver metropolitan area, British Columbia, Canada. Vaccine. 2024. PMID: 38797627. doi:10.1016/j.vaccine.2024.05.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。